Micell's intellectual property portfolio contains more than 80 patents that only partially reflect our expertise in a variety of processes employing supercritical's across a wide range of materials, configurations, products, and manufacturing systems. This broad portfolio reflects the enabling of 'limus drug performance with sustained-release kinetics, enhanced stability, increased yields, and rapid product development.
Micell's intellectual property portfolio includes patents and patent applications either owned by Micell, or exclusively licensed from distinguished institutions such as Battelle Memorial Institute. Micell owns or controls intellectual property covering unique bioabsorbable drug delivery formulations and related process methods in the following biomedical applications:
- Controlling the morphology, distribution and drug-delivery characteristics of drugs in sustained-release coatings and drug delivery materials
- Coating of complex medical devices with drug/polymer formulations
- 'Dry', low-temperature drug/polymer coating processes that maintain the structure and morphology of therapeutic agents
With its first core patent expiration years away in 2022, Micell is continuing to innovate and complement its patent portfolio.